NASDAQ · Biotechnology

ADPT (ADPT) Stock

$24.34 -2.33% NASDAQ: ADPT Healthcare

Valuation

MetricValue
Price$24.34
Market Cap$3.90B
P/E Ratio-69.84
P/B Ratio13.03
P/S Ratio9.57
EPS (TTM)$-0.39
52-Week High$26.74
52-Week Low$9.96
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-23.95%
ROA-5.74%
ROCE-25.33%
Gross Margin75.26%
Operating Margin-15.82%
Net Margin-16.82%
Debt/Equity0.96
Current Ratio3.33

Annual Financials (USD)

Metric20212022202320242025
Revenue$154.0M$185.0M$170.0M$179.0M$277.0M
Operating Profit$-209.0M$-200.0M$-227.0M$-163.0M$-57.0M
Net Profit$-207.0M$-200.0M$-225.0M$-159.0M$-59.0M
EPS$-1.46$-1.00$-1.56$-1.08$-0.39
Op Margin-135.4%-108.0%-133.3%-90.8%-20.6%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$923.0M$857.0M$661.0M$539.0M$513.0M
Total Liabilities$319.0M$393.0M$353.0M$337.0M$288.0M
Cash$139.0M$90.0M$65.0M$48.0M$70.0M
Borrowings$112.0M$108.0M$99.0M$89.0M$281.0M

Latest News

An Adaptive Biotechnologies Insider Sold $8.5 Million in Stock After an 85% Run Motley Fool · Jul 12, 2026 Adaptive Biotechnologies to Report Second Quarter 2026 Financial Results on July 29, 2026 GlobeNewswire · Jul 9, 2026 Adaptive Biotechnologies Insider Sold Shares Worth $8,501,149, According to a Recent SEC Filing MT Newswires · Jul 8, 2026 Adaptive Biotechnologies Insider Sold Shares Worth $2,157,683, According to a Recent SEC Filing MT Newswires · Jul 7, 2026 Imviva Biotech Granted FDA IDE Authorization for Cancer Treatment Trial Exec Edge · Jun 30, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-193.0M$-184.0M$-156.0M$-95.0M$-46.0M
Investing Cash Flow$119.0M$-13.0M$119.0M$74.0M$35.0M
Financing Cash Flow$0$0$0$0$0
Net Cash Flow$16.0M$-49.0M$-25.0M$-17.0M$22.0M
Free Cash Flow$-254.0M$-200.0M$-167.0M$-99.0M$-49.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-111.40
EV / EBITDA-94.49
FCF Yield-1.04%
Quick Ratio3.22
Interest Coverage-4.75
Return 1Y89.26%
Return 3Y277.10%
Return 5Y-23.91%

Ownership

Insiders Held1.84%
Institutions Held96.60%
Institutions Float Held98.41%
Institutional HolderSharesReport Date
Viking Global Investors, L.P.29,993,7082026-03-31
Blackrock Inc.13,303,0252026-03-31
Vanguard Capital Management LLC6,094,1442026-03-31
Westfield Capital Management Co LP5,436,7182026-03-31
Vanguard Portfolio Management LLC4,491,4742026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPL $325.13 +2.61% 35.78 $4.78T 0.34%
MSFT $501.02 -1.24% 27.58 $3.72T 0.73%
GOOGL $335.02 -1.28% 16.98 $4.05T 0.26%
AMZN $254.92 -1.87% 20.66 $2.74T 0.00%
META $578.54 +1.08% 21.41 $1.47T 0.36%

About ADPT

ADPT stock trades at $24.34 with a market capitalization of $3.90B. The stock is valued at a price-to-earnings (P/E) ratio of -69.84, price-to-book of 13.03, price-to-sales of 9.57. Over the past 52 weeks the stock has ranged between $9.96 and $26.74, and currently trades 9.0% below its 52-week high.

On profitability, ADPT generates a return on equity (ROE) of -23.95%, return on capital employed of -25.33%, an operating margin of -15.82%, a net profit margin of -16.82%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1159.93 +0.28% JNJ Drug Manufacturers - General $271.19 +2.01% ABBV Drug Manufacturers - General $259.99 +1.39% MRK Drug Manufacturers - General $149.94 +1.48% UNH Medical - Healthcare Plans $396.30 +1.77% NVS Drug Manufacturers - General $161.25 +6.04% AZN Drug Manufacturers - General $162.47 +0.21% AMGN Drug Manufacturers - General $438.12 +1.92% TMO Medical - Diagnostics & Research $600.50 -2.69% NVO Biotechnology $45.12 -0.46% ABT Medical - Devices $108.97 -1.26% GILD Drug Manufacturers - General $149.92 +2.45%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides